GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Aclarion ACON · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.75

+5.42%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Aclarion

From its filings with the US Securities and Exchange Commission

SEC filings

Aclarion is based in Broomfield, Colorado and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ACON. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $75,730 and a net loss of $7.2m. At that date it held total assets of $13.7m and shareholders' equity of $12.8m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Technology
Listed since
22 Apr 2022
Employees
7
Head office
8181 ARISTA PLACE, BROOMFIELD, CO, 80021
Incorporated in
DE
Classification
Services-Medical Laboratories
Filer status
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. David NealDirector$25,000
  • Dr. Jeff ThramannExecutive Chairman of the Board, since 2020$381,069
  • Mr. Brent NessPresident, Chief Executive Officer, Director, since 2021$381,069
  • Mr. Gregory GouldChief Financial Officer
  • Mr. Ryan BondChief Strategy Officer$226,875
  • Mr. William WesemannLead Independent Director$40,000
  • Dr. Scott BreidbartIndependent Director$40,000
  • Mr. Steve DeitschIndependent Director$45,000
  • Ms. Amanda WilliamsIndependent Director$35,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Aclarion employs only seven full-time staff members.
  • The company utilizes proprietary biomarker technology.
  • IPO occurred on April 22, 2022.

Weaknesses

  • The workforce size is extremely small.
  • Operations are limited to a single city.
  • Reliance on a narrow patient demographic.

Opportunities

  • Augmented intelligence can improve data analysis.
  • Chronic low back pain affects many patients.
  • Normative data sets allow individualized metrics.

Threats

  • Healthcare sector regulations may change.
  • Competitors could develop similar biomarkers.
  • Limited employee count restricts scalability.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.